EZH-302

EU Clinical Trials Register

 

New phase III clinical study with tazemetostat for patients with relapsed/refractory follicular lymphoma Tazemetostat - orally administered, first-in-class small molecule EZH2 inhibitor

 
Zusätzliche Dokumente